Groundbreaking Lymphoma Treatments May Bring Great Change
What was approval based on?
The approval of Aliqopa was based on data from a single-arm trial that included 104 patients with follicular B-cell non-Hodgkin lymphoma who had not responded well to at least two traditional treatments. In the trial, 59 percent of patients experienced complete or partial shrinkage of tumors caused by the lymphoma. There is still more extensive testing required in order to distribute the medicine on a larger scale.
